This year marked a pivotal moment in the quest to treat Huntington’s disease, a rare but devastating form of dementia. Scientists found that an experimental gene therapy slowed the condition’s ...
Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.71. The Food and Drug Administration this week granted approval to a new gene ...
Joint presentation by Orchestra BioMed and Medtronic leadership to discuss ongoing strategic collaboration for development and commercialization of AVIM Therapy for treatment of uncontrolled ...
“Bubble boy disease” was once a death sentence. A scientific breakthrough changed that. By Simar Bajaj A common cold was enough to kill Cora Oakley. Born in Morristown, N.J., with virtually no immune ...
SetPoint System® is first-of-its-kind neuroimmune modulation device for the treatment of adults living with moderate-to-severe rheumatoid arthritis SetPoint Medical, a commercial-stage medical ...
Dear Annie: Every year, I host Thanksgiving for my family, and every year I start out with the same hopeful thought: “This time will be different.” I picture everyone laughing, passing dishes around, ...
The FDA has put a clinical hold on a Tenaya Therapeutics gene therapy study while the biotech works to standardize activities related to the immunosuppression regimen across trial sites. Tenaya said ...
BERKELEY, Calif., Nov. 02, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced that it will ...
A recent study published in Redox Biology by researchers from the UAB Department of Pathology revealed that too much of a good thing, specifically excessive antioxidants, can lead to heart damage. The ...
The European Medicines Agency (EMA) has recommended the refusal of marketing authorization for Rezurock (belumosudil) for treating patients 12 years or older with chronic graft-vs-host disease (cGvHD) ...
Beyond the Trials: Real-World Considerations for Sentinel Lymph Node Biopsy Omission in Early Breast Cancer Study design, end points, and statistical analysis for REACH2 (ClinicalTrials.gov identifier ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback